| Bioactivity | Ponatinib-d8 is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. | ||||||||||||
| Name | Ponatinib-d8 | ||||||||||||
| CAS | 1562993-37-6 | ||||||||||||
| Formula | C29H19D8F3N6O | ||||||||||||
| Molar Mass | 540.61 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412. |
Ponatinib-d8
CAS: 1562993-37-6 F: C29H19D8F3N6O W: 540.61
Ponatinib-d8 is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor w
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.